

## A REVIEW ON EFFECT OF LIPID METABOLISM IN GALLSTONE DISEASE

Lipitha A.\* and Aji Varghese

Department of Pharmacy Practice, St. James College of Pharmaceutical Sciences, St. James Hospital Trust  
Pharmaceutical Research Center (DSIR Recognized), Chalakudy, Thrissur, Kerala.**\*Corresponding Author: Lipitha A.**Department of Pharmacy Practice, St. James College of Pharmaceutical Sciences, St. James Hospital Trust Pharmaceutical Research Center  
(DSIR Recognized), Chalakudy, Thrissur, Kerala.

Article Received on 12/07/2021

Article Revised on 02/08/2021

Article Accepted on 22/08/2021

## INTRODUCTION

Gallstone diseases are the leading cause for hospital admissions related to gastrointestinal problems. They are most common and costly. Gallbladder is a gastrointestinal organ that concentrates and stores hepatic bile for delivery into the intestinal lumen during the food intake cycles for lipid digestion and absorption, and that it is the organ where gallstones (GS) form, producing GB disease (GBD).<sup>[1]</sup> Cholesterol gallstone formation is based upon supersaturated bile formation and pigment stones are formed in bile rich in bilirubin. Thus, defects of hepatic metabolism of lipids and organic anions lead to biliary stones.<sup>[2]</sup>

Cholesterol (CH) GS are present in approximately 80% of patients with GBD. The remaining GS patients harbor black pigment stones, mainly composed of calcium bilirubinate, and brown pigment or mixed stones.<sup>[1]</sup> Most of the risk factors for cholesterol gallstone formation are not modifiable such as ethnic background, increasing age, female gender and family history or genetics. Conversely, the modifiable risk factors for cholesterol gallstones are obesity, rapid weight loss and a sedentary lifestyle. The rising epidemiology of obesity and the metabolic syndrome predicts an escalation in the frequency of cholesterol gallstone. Risk factors for biliary sludge include pregnancy, drugs like ceftriaxone, octreotide and thiazide diuretics, and total parenteral nutrition or fasting. Diseases like cirrhosis, chronic hemolysis and Crohn's disease are risk factors for black pigment stones.<sup>[3]</sup> The major purpose of this article is, to review some of the metabolic links between abnormalities of lipid metabolism commonly found in GB functions and GBD.

**Biliary Cholesterol**

Cholesterol is an insoluble molecule that is critical for cellular structure and function. Homeostasis of this compound is kept by biliary elimination from the liver, where it is catabolized to bile salts for a regulation of pool size.<sup>[2]</sup> Free cholesterol represents the least concentrated lipid in bile. Like bile acids, the principle source of biliary cholesterol appears to be lipoprotein free cholesterol coupled with a modest contribution from the newly synthesized pool of cholesterol. Biliary cholesterol and lecithin have their immediate origins within the hepatocyte and depend on bile salts for their secretion into bile. Most of the biliary lecithin is synthesized by the process of de novo within the

hepatocytes however, some may be derived from the surface coat of serum lipoproteins.

**Gallbladder**

Gallbladder epithelium can absorb lipid from Bile. Bile is the only significant pathway for elimination of excess cholesterol from the body, either as free cholesterol or as bile salts. The GB plays a central role in the digestion and absorption of lipids present in the diet. It stores and concentrates hepatic bile secreted by the liver during periods of fasting and then sends it to the intestine during food intake.

**Physical and Chemical events in Gallbladder**

In normal individuals, differential absorption of bile salts, cholesterol and phospholipid functions to reduce the saturation of bile with cholesterol. Impaired lipid absorption can lead to sustained supersaturation of bile with cholesterol and therefore predispose to cholesterol crystallization. Defective gallbladder motility also plays a key role in cholesterol cholelithiasis. Abnormalities in both filling and emptying, defects in contractility are attributable to excess membrane accumulation in gallbladder smooth muscle cells of biliary cholesterol. This will result in diminished gallbladder relaxation. Further more, the enhanced synthesis and hypersecretion of mucin in the gallbladder enhance the cholesterol crystallization and growth and macroscopic gallstones form eventually under the circumstance of gallbladder dysfunction.<sup>[2,3]</sup>

**Bile Secretion**

Bile consists of cholesterol, phospholipids and bile salts. Bile secretion is stimulated by food intake. The presence of food in the duodenum (especially fat) induces

secretion of cholecystokinin (CCK) by mucosal endocrine cells which, in turn, causes contraction and release of bile by the gallbladder. The failure of gallbladder contraction can result in stasis of gallbladder bile and can enhance the formation of biliary "sludge" characterized by the accumulation of a lipid-mucin-proteinaceous debris with calcium bilirubinate salts that generally precedes gallstone formation.

Physiological events associated with digestion and absorption stimulate hepatic bile synthesis and secretion to effectively increase the concentration of biliary micelles, i.e. phospholipid, bile acid, and free cholesterol, and decrease the relative biliary cholesterol concentration.

### Gallstones

Gallstones are the common cause of Biliary tract dysfunction. A history of gallstones appears to carry the highest risk for gallbladder cancer, but not all people with gallbladder cancer have cholelithiasis.<sup>[4]</sup> The pathogenesis of cholesterol gallstones involves a complex set of variables affecting the relative concentration of bile acid, phospholipid, free cholesterol, and protein during their collective flux through the biliary system. The stones with cholesterol concentrations higher than 50% are considered to be cholesterol stones and 70% to 80% of gallstones are cholesterol stones.

### Pathology

Biliary Sludge is the precursor of gallstones. It consists of Calcium Bilirubinate, cholesterol microcrystals and mucin. The sludge develops during gallbladder stasis. Most of them are asymptomatic and disappears when primary condition resolves. Alternatively, a sludge can evolve into gallstones or migrate into biliary tract, obstructing the ducts and leads to Biliary colic, cholangitis, pancreatitis. The following conditions must be present to permit the formation of cholesterol gallstones; Bile must be supersaturated with cholesterol, Nucleation must be kinetically favourable, Cholesterol crystals must remain in the gall bladder long enough to aggregate into stones.

### Diagnosis

The best epidemiological screening method to accurately determine point prevalence of gallstone disease is ultrasonography. More reliable epidemiological studies now use transabdominal ultrasound to screen robust numbers in defined asymptomatic populations. Ultrasonography is an ideal means to quantitate the frequency of gallstone disease, being a noninvasive and safe imaging technique that accurately can detect the point prevalence of gallstones in a defined asymptomatic population.

The number of surgical procedures for cholelithiasis has risen markedly in developed countries since 1950.<sup>[5]</sup> The introduction of laparoscopic cholecystectomy in 1989

further increased the cholecystectomy rate.<sup>[6,7]</sup> From 1990 to 1993, there was a 28% escalation in the number of cholecystectomy performed.<sup>[8]</sup> The change in practice emanated from the laparoscopic surgical approach, which represented a less invasive, more cosmetically acceptable operation while providing a lower surgical risk compared to the then conventional or "open" procedure. This likely resulted in more surgeries being done in patients previously thought to be too high a risk, or in those with minimal symptoms. Although there is undoubtedly an element of overuse, cholecystectomy is now the most common elective abdominal surgery.<sup>[3,9]</sup>

### Lipid Metabolism

Cholesterol is water insoluble and is rendered water soluble by aggregation with bile salts and lecithin secreted into bile. When cholesterol concentration exceeds the solubilising capacity of bile, cholesterol can no longer remain dispersed and nucleates into the solid cholesterol monohydrate crystals.<sup>[10]</sup> The known factors associated with cholesterol gallstones include cholesterol hypersecretion and supersaturation, bile salt and phospholipid concentrations, crystal nucleation, gallbladder dysmotility and gallbladder absorption and secretion functions. Cholesterol gallstone disease is a metabolic abnormality, which can be correlated with adiposity, diabetes mellitus and lipid abnormality.

LDL transports cholesterol from the liver to the peripheral tissues, and HDL transports cholesterol from the peripheral tissues to the liver. Triglycerides are major metabolites through which energy can be stored in adipose tissue and transported throughout the organism for maintaining energy homeostasis.

When dietary fat enters the plasma from the small intestine in the form of chylomicrons, and they then deliver Free Fatty Acids (FFA) from Triglycerides (TG) to the tissues that express lipoprotein lipase. Once approximately two thirds of their TGs are unloaded in peripheral tissues, chylomicron remnants containing the remaining TGs and CH esters are quickly taken in by the liver.<sup>[8]</sup> Abnormal accumulation of hepatic lipids occurs when the amount of FFAs and CH entering the hepatocytes exceeds their exit. FFA flow between the different tissues changes according to the nutritional state of the subject. Similarly, cellular CH content will depend on the uptake from plasma lipoproteins and the level of endogenous synthesis. In the feeding stage, FFAs travel bound to albumin towards the tissues to be stored in adipose tissue. The endogenous secretion of TGs and CH to the plasma is carried out from the liver in the form of VLDL and is regulated by food intake cycles. This regulation is dependent on insulin effects that decrease the hepatic production of VLDL, which is increased in states of Insulin Resistance.<sup>[9]</sup> Serum TG concentrations after ablation of the GB, suggest that cholecystectomy and GBD disease may impact negatively on the metabolic homeostasis of the whole body.

High serum cholesterol, high serum LDL, and low serum HDL levels may be expected to increase cholesterol excretion with bile and cause cholesterol gallstone disease. The relationship between serum cholesterol, LDL, and HDL levels and cholesterol gallstone formation is multifactorial and complex and is also dependent on other individual properties. A low HDL cholesterol and hypertriglyceridemia carry an increased risk of developing stones. In contrast, various research studies does not describe a definite association with GS disease and hypercholesterolemia. High homocysteine levels may also correlate with gallstone disease.

Both the metabolic syndrome and diabetes mellitus are risk factors for gallstone disease.<sup>[11]</sup> Insulin resistance predisposes to cholesterol gallstone formation,<sup>[12,13]</sup> suggesting an altered cholesterol and bile salt metabolism. Hepatic insulin resistance may act by enhancing hepatic cholesterol secretion, depressing bile salt synthesis and/or impairing gallbladder motility.<sup>[14-16]</sup>

## CONCLUSION

Recent studies have shown that hypertriglyceridaemia, hypercholesterolemia and low level of high density lipoprotein cholesterol (HDL) a common finding in patients with cholelithiasis. Bile is the only significant pathway for elimination of excess cholesterol from the body, either as free cholesterol or as bile salts. Abnormalities of lipid metabolism in GBD are related to both primary abnormalities in the regulation of biliary lipid secretion and GB function, and abnormalities of whole body lipid metabolism are commonly found in IR states, particularly obesity, Type 2 diabetes and Non-Alcoholic Fatty liver disease (NAFLD). TC, TG, LDL are risk factors, while HDL is a protective factor.

## REFERENCE

- Silvana Zanlungo, Attilio Rigotti, Juan Francisco Miquel et al. Abnormalities of lipid metabolism, gallstone disease and gallbladder function, 6(3): 315-325.
- Susumu Tazuma, Keishi Kanno, Akiko Sugiyama et al. Nutritional factors (nutritional aspects) in biliary disorders: Bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction, Journal of Gastroenterology and Hepatology, 2013; 28: 103-107.
- Nakai K, Tazuma S, Ochi H et al. Does bilirubin play a role in the pathogenesis of both cholesterol and pigment gallstone formation Direct and indirect influences of bilirubin on bile lithogenicity. Biochim. Biophys. Acta, 2001; 1534: 78-84.
- Laura M Stinton and Eldon A Shaffer. Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer Gut and Liver, April 2012; 6(2): 172-187.
- Legorreta AP, Silber JH, Costantino GN et al. Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy. JAMA, 1993; 270: 1429-1432.
- Marshall D, Clark E, Hailey D. The impact of laparoscopic cholecystectomy in Canada and Australia. Health Policy, 1994; 26: 221- 230.
- Kang JY, Ellis C, Majeed A, et al. Gallstones: an increasing problem: a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther, 2003; 17: 561-569.
- Nenner RP, Imperato PJ, Rosenberg C et al. Increased cholecystectomy rates among Medicare patients after the introduction of laparoscopic cholecystectomy, Journal of Community Health, 1994; 19: 409-415.
- Ransohoff DF, Gracie WA, Wolfenson LB et al. Prophylactic cholecystectomy or expectant management for silent gallstones. A decision analysis to assess survival. Ann Intern Med, 1983; 99: 199-204.
- Ajaz Ahmad Malik, Mohd Lateef Wani\*, Shahid Iqbal Tak et al. Association of dyslipidaemia with cholelithiasis and effect of cholecystectomy on the same, International Journal of Surgery, 2011; 9: 641-642.
- Ganong WF. Gastrointestinal function, Review of Medical Physiology, Columbus, McGraw-Hill Professional, USA, 2005; 467-479.
- Adiels M, Olofsson SO, Taskinen MR et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2008; 28(7): 1225-1236.
- Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D, et al. Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol, 2005; 11: 1653-1657.
- Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology, 2000; 31: 299-303.
- Nervi F, Miquel JF, Alvarez M, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol, 2006; 45: 299-305.
- Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med, 2008; 14: 778-782.
- Twisk J, Hoekman MF, Lehmann EM et al. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol-7-alpha-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology, 1995; 21: 501-510.
- Nakeeb A, Comuzzie AG, Al-Azzawi H, Sonnenberg GE, Kissebah AH, Pitt HA. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg, 2006; 10: 940-948.
- Van Erpecum KJ, Pathogenesis of cholesterol and pigment gallstones: an update. Clin. Res. Hepatol. Gastroenterol, 2011; 35(4): 281-287.
- Stinton LM, Myers RP, Shaffer EA, Epidemiology of gallstones, Gastroenterol. Clin. North Am, 2010; 39(2): 157-169.

21. Johansson S, Wilhelmsen L, Lappas Get al. High lipid levels and coronary disease in women in Goteborgeoutcome and secular trends: a prospective 19 year follow-up in the BEDA study, *Eur Heart J*, 2003; 24: 704-16.
22. Singh BK, Mehta JL, Management of dyslipidemia in the primary prevention of coronary heart disease. *Curr Opin Cardiol*, 2002; 17: 503- 11.
23. Berhane T, Vetrhus M, Hausken T et al. Pain attacks in non-complicated and complicated gallstone disease have a characteristic pattern and are accompanied by dyspepsia in most patients: the results of a prospective study, *Scand J Gas troenterol*, 2006; 41: 93-101.
24. Weinert CR, Arnett D, Jacobs D Jr et al. Relationship between persistence of abdominal symptoms and successful outcome after cholecystectomy, *Arch Intern Med*, 2000; 160: 989-995.
25. Vetrhus M, Berhane T, Soreide O, Sondena K. Pain persists in many patients five years after removal of the gallbladder: obser vations from two randomized controlled trials of symptomatic, noncomplicated gallstone disease and acute cholecystitis, *J Gas trointest Surg*, 2005; 9: 826-831.
26. Mertens MC, Roukema JA, Scholtes VP, De Vries J. Risk assess ment in cholelithiasis: is cholecystectomy always to be preferred, *J Gastrointest Surg*, 2010; 14: 1271-1279.
27. Thistle JL, Longstreth GF, Romero Y et al. Factors that predict relief from upper abdominal pain after cholecystectomy, *Clin Gastroenterol Hepatol*, 2011; 9: 891-896.
28. Shaffer E. Acalculous biliary pain: new concepts for an old entity, *Dig Liver Dis*, 2003; 35(3): S20-S25.
29. DiBaise JK, Richmond BK, Ziessman HH, et al. Cholecystokinin cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. *Clin Gastroenterol Hepatol*, 2011; 9: 376- 384.
30. Gurusamy KS, Junnarkar S, Farouk M et al. Cholecystectomy for suspected gallbladder dyskinesia, *Cochra ne Database Syst Rev*, 2009; 1: 86.